ARWR

TentativeAI Memo

Arrowhead

As of 2026-09-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

ARO-ALK7 update can reinforce or weaken the obesity-platform thesis • 2026-12-31

Base target: $78 / p=50% prob

Biggest risk

Commercial evidence remains immature: fiscal Q3 REDEMPLO revenue was about $2.4 million despite stronger prescription activity, while the quarterly net loss was approximately $194.3 million and R&D expense approximately $198 million. ARO-DIMER-PA data are interim and single-dose, and favorable biomarker changes do not establish cardiovascular outcomes or later-stage success. The $215 million priority-review-voucher outlay also raises execution stakes [#PR-EARNINGS-2026-08-05].

Invalidation

Break below $45 or thesis failure.

What would change my mind?

The thesis now combines an expanding commercial product, pivotal plozasiran efficacy in severe hypertriglyceridemia, approximately $1.6 billion of quarter-end cash and investments, and multiple independently advancing RNAi programs. ARO-DIMER-PA's dual-target single-dose activity offers additional platform validation, while stronger REDEMPLO revenue conversion could shift valuation from pipeline optionality toward a commercial-growth framework [#SEC-8K-2026-08-04] [#IR-2026-09-15].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-17

Base target

$78

p=50%

Bull target

$105

p=25%

Bear target

$45

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

REDEMPLO launch must convert prescription growth into meaningful revenue
ARO-DIMER-PA requires multiple-dose and fuller safety validation
Plozasiran severe-hypertriglyceridemia regulatory execution is the major franchise expansion lever

BearKey bullets

ARO-DIMER-PA evidence is interim, single-dose, and biomarker-based; multiple-dose safety, durability, dose selection, and clinical-outcome relevance remain unproven [#IR-2026-09-15].
Fiscal Q3 operating investment was high, including approximately $198 million of R&D expense and $47 million of SG&A expense, while the net loss widened to approximately $194.3 million [#PR-EARNINGS-2026-08-05].
Ionis already competes directly in FCS and sHTG, while Silence is advancing overlapping RNAi cardiometabolic targets; competitive efficacy, safety, dosing, pricing, payer access, and development speed may limit Arrowhead's commercial or pipeline differentiation [#IR-IONS-2026-06-24] [#IR-SLN-2026-03-05].

WatchKey bullets

ARO-ALK7 update can reinforce or weaken the obesity-platform thesis

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $78 (p=50%)

Target spread vs base: +35% / -42%

Scenario probabilities

Bull Target: $105 (p=25%)Base Target: $78 (p=50%)Bear Target: $45 (p=25%)

Commentary

Company-source news flow is fundamentally constructive, led by pivotal plozasiran results, improving early REDEMPLO activity, and positive ARO-DIMER-PA biomarker data. However, the $65.79 September 16 anchor is well below the roughly $87 prices of the August 18 director sales, and secondary coverage characterized the September 15 response as a sharp sell-the-news decline. That causal framing and the exact event-day move were not independently confirmed, so the reaction is treated as evidence of demanding expectations rather than a definitive clinical reassessment. Social coverage is unavailable, and robust post-data analyst revisions are also unavailable. Direct comparison with Ionis highlights meaningful commercial competition, while Silence provides a relevant RNAi cardiometabolic development benchmark. The setup remains moderately positive but monitoring-oriented.

As of 2026-09-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

REDEMPLO launch must convert prescription growth into meaningful revenue
ARO-DIMER-PA requires multiple-dose and fuller safety validation
Plozasiran severe-hypertriglyceridemia regulatory execution is the major franchise expansion lever

Scenarios

Bull Target (Scenario probability)

$105 / p=25% prob

Base Target (Scenario probability)

$78 / p=50% prob

Bear Target (Scenario probability)

$45 / p=25% prob

Analysis 2026-09-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
ARO-ALK7 update can reinforce or weaken the obesity-platform thesis
Management said it intended to provide a data update primarily focused on ARO-ALK7 toward the end of 2026. Evidence of durable target knockdown, weight or body-composition benefit, and an acceptable safety profile would broaden value beyond plozasiran; inconclusive efficacy would narrow pipeline credit [#EARNINGS-TRANSCRIPT-2026Q3].
Prob 60.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

REDEMPLO launch must convert prescription growth into meaningful revenue
2026-11-30
Fiscal Q3 prescription volume roughly doubled and more than 400 practitioners had prescribed REDEMPLO, but quarterly commercial revenue remained only about $2.4 million. Subsequent results need to demonstrate paid-claim persistence, reimbursement conversion, and accelerating revenue rather than prescription activity alone [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-05].
Prob 65% • Move 9% • Priced-in 55%

Long-term Catalysts

Months to a year

ARO-DIMER-PA requires multiple-dose and fuller safety validation
2027-09-17
Arrowhead reported that interim single-dose Phase 1/2a data produced mean maximal reductions of 72% in PCSK9, 88% in APOC3, 54% in LDL-C, and 73% in triglycerides, with no drug-related serious adverse events reported. The study remains ongoing for multiple-dose safety and tolerability, while additional results are planned for an upcoming medical congress; timing was not disclosed [#IR-2026-09-15].
Prob 60% • Move 14% • Priced-in 60%
Plozasiran severe-hypertriglyceridemia regulatory execution is the major franchise expansion lever
2027-09-17
SHASTA-3 and SHASTA-4 met their primary and all prespecified secondary endpoints, with median triglyceride reductions of 79% and 81% and a reported 78% reduction in acute-pancreatitis events across the study population. Arrowhead acquired a priority-review voucher to potentially accelerate the planned supplemental application, but approval, label breadth, reimbursement, and launch timing remain unresolved [#SEC-8K-2026-08-04].
Prob 70% • Move 18% • Priced-in 65%

Risks

ARO-DIMER-PA evidence is interim, single-dose, and biomarker-based; multiple-dose safety, durability, dose selection, and clinical-outcome relevance remain unproven [#IR-2026-09-15].
Fiscal Q3 operating investment was high, including approximately $198 million of R&D expense and $47 million of SG&A expense, while the net loss widened to approximately $194.3 million [#PR-EARNINGS-2026-08-05].
Ionis already competes directly in FCS and sHTG, while Silence is advancing overlapping RNAi cardiometabolic targets; competitive efficacy, safety, dosing, pricing, payer access, and development speed may limit Arrowhead's commercial or pipeline differentiation [#IR-IONS-2026-06-24] [#IR-SLN-2026-03-05].
Plozasiran expansion remains exposed to filing timing, FDA review, label breadth, reimbursement, launch execution, and the economic return on the $215 million priority-review voucher.
REDEMPLO prescriptions may convert slowly into paid, recurring revenue because diagnosis, physician education, reimbursement, and patient onboarding remain demanding.
Two directors reported open-market sales totaling 13,600 shares on August 18, 2026; these transactions are a monitoring signal, not evidence about operating performance [#SEC-FORM4-2026-08-20].

Peers

Symbol	Summary
IONS	Ionis is the closest commercial and indication-level comparator. TRYNGOLZA, like REDEMPLO, targets APOC3 and is approved for FCS; Ionis also received an expanded U.S. sHTG approval in June 2026. Its product revenue, payer access, pricing, prescription conversion, and broader-indication launch trajectory provide direct benchmarks for REDEMPLO and plozasiran [#IR-IONS-2026-06-24].
MDGL	Madrigal is an indication-adjacent comparator and development partner rather than an RNAi-platform peer. Its relevance comes from Arrowhead's license of ARO-PNPLA3, which included a reported $25 million upfront payment and up to $975 million in potential milestones and royalties, making MASH-category development and partnership execution useful benchmarks for that program [#PR-EARNINGS-2026-08-05].
SLN	Silence Therapeutics is a direct RNAi-platform and cardiometabolic-development comparator. Its pipeline includes Phase 3-ready zerlasiran targeting LPA, Phase 1 SLN312 targeting ANGPTL3 in dyslipidemia, and preclinical SLN098 targeting INHBE in obesity; relative trial progression, durability, safety, partnering, and financing therefore help benchmark Arrowhead's ARO-DIMER-PA, zodasiran, and ARO-INHBE programs [#IR-SLN-2026-03-05].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-17

Loading AI feed…

Symbol

Summary

IONS

Ionis is the closest commercial and indication-level comparator. TRYNGOLZA, like REDEMPLO, targets APOC3 and is approved for FCS; Ionis also received an expanded U.S. sHTG approval in June 2026. Its product revenue, payer access, pricing, prescription conversion, and broader-indication launch trajectory provide direct benchmarks for REDEMPLO and plozasiran [#IR-IONS-2026-06-24].

MDGL

Madrigal is an indication-adjacent comparator and development partner rather than an RNAi-platform peer. Its relevance comes from Arrowhead's license of ARO-PNPLA3, which included a reported $25 million upfront payment and up to $975 million in potential milestones and royalties, making MASH-category development and partnership execution useful benchmarks for that program [#PR-EARNINGS-2026-08-05].

SLN

Silence Therapeutics is a direct RNAi-platform and cardiometabolic-development comparator. Its pipeline includes Phase 3-ready zerlasiran targeting LPA, Phase 1 SLN312 targeting ANGPTL3 in dyslipidemia, and preclinical SLN098 targeting INHBE in obesity; relative trial progression, durability, safety, partnering, and financing therefore help benchmark Arrowhead's ARO-DIMER-PA, zodasiran, and ARO-INHBE programs [#IR-SLN-2026-03-05].